Trial Profile
Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 16 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record